Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 226
Ph III recruiting: 25
Growth YoY: +3.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 201–203 of 203 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00612495	Endometrial Cancer - LOHP Alone and With 5FU	completed	Phase 2	31	SanofiINDUSTRY	1	Feb 11, 2008	clinicaltrials
NCT00401635	END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin	completed	Phase 2	42	National Cancer Institute, NaplesOTHER	1	Sep 5, 2007	clinicaltrials